A team of biologists and biomedical researchers at UC San Diego has developed a new method to determine if bacteria are susceptible to antibiotics within a few hours, an advance that could slow the appearance of drug resistance and allow doctors to more rapidly identify the appropriate treatment for patients with life threatening bacterial infections.
In a paper published online this week in the journal EBioMedicine, the scientists reported the development of a rapid susceptibility test for Staphylococcus aureus, a bacterium that causes some 60 percent of hospital-acquired infections and which has spread in communities, causing pneumonia and a variety of skin and tissue infections in both healthy and immune-compromised individuals.
The development is important, say biomedical scientists, because of the critical need for physicians to rapidly discriminate between drug resistant strains (commonly termed MRSA for methicillin-resistant S. aureus) and drug sensitive strains, since these infections can progress rapidly, especially MRSA strains with additional resistance to newer antibiotics designed to treat pathogens that are now appearing in hospitals.
According to the Centers for Disease Control and Prevention, antibiotic resistance causes two million illnesses and 23,000 deaths annually, costing the U.S. economy approximately $20-billion a year in direct health care costs and nearly eight million extra days in the hospital. Indeed, bacteria are evolving resistance to antibiotics much more quickly than global biomedical research efforts are delivering new drugs to market, leading to the appearance of infections caused by bacteria that are now resistant to every therapy.
Rapid antimicrobial susceptibility testing allows doctors to discriminate between infections caused by drug sensitive bacteria, which can be treated with safe and effective antibiotics developed in what scientists call the golden age of drug discovery (the mid-20th century) such as penicillin, and those caused by drug resistant bacteria, which might require newer antibiotics, such as daptomycin or cubicin. This approach will decrease the emergence of resistance by reserving the newest drugs for those infections where they are most needed.
The interdisciplinary team at UC San Diego was comprised of two infectious-disease specialists in the School of Medicine, Victor Nizet, MD, and George Sakoulas, MD; two biologists in the Division of Biological Sciences, Kit and Joe Pogliano; and Diana Quach, a bioengineering graduate student. The scientists applied a method previously developed in the Pogliano laboratories for drug discovery to antibiotic susceptibility testing.
“Previously we developed a microscopy-based method that performs an autopsy on bacterial cells that allows us to determine how each cell died, and we have shown that this method can identify new antibiotics and help understand how these antibiotics work,” said Kit Pogliano, a professor of biology at UC San Diego who headed the research team. “We tested to see if this method could be applied to antibiotic susceptibility testing. Surprisingly, we not only found that our method was able to accurately differentiate sensitive S. aureus strains from resistant MRSA strains, but that we were able to identify two subgroups of MRSA strains, one of which is susceptible to combinations of antibiotics that could be used in the hospital. We are excited by the accuracy and speed of this test, as well as by its unanticipated ability to identify these two types of MRSA infections, which would have been missed by other tests.”
Examining single cells has two key advantages over other testing methods, say the researchers. First, it is rapid, cutting days off the time for typical culture-based assays. It often takes days for a doctor to receive information on resistance, and this means that patients with life-threatening infections are often treated with the assumption that the infection is drug-resistant. Second, this method does not rely on having any detailed understanding of the bacterium causing the infection, or of the genes that convey resistance. This is particularly important in this case, since resistance to the drugs used to treat MRSA infections arise by several evolutionary pathways via different combinations of mutations, and it could also provide rapid treatment information for newly emerging bacterial pathogens, such as that which caused the infections transmitted by endoscopes.
“Regardless of the type of bacterium, a healthy and growing bacterium looks different from a dead bacterium, so whenever we detect a difference in how the cells look, we know that the bacterium is sensitive to the antibiotic we have applied. When we combine careful culture conditions, cutting edge imaging methods and a detailed quantitative analysis, we can turn this simple approach into a reliable test,” said Joe Pogliano, a professor of biology.
“Rapid and precise identification of antibiotic sensitivity patterns allows the most potent and effective drug to be administered,” said Nizet, a professor of pediatrics and pharmacy. “Equally important, more specific antibiotic therapy can help preserve the normal bacteria living in our gut microbiome that play an important role in our health and immune system function.”
The UC San Diego biologists say their new method has the potential to be applied to many different types of bacteria. “Our new method worked surprising well at rapidly detecting antibiotic resistant strains of S. aureus,” said Diana Quach, a graduate student and lead author on the study. “We are now optimizing it to provide a more accurate test for other types of antibiotic resistant bacteria, such as Pseudomonas aeruginosa.”
The Latest on: Antibiotic susceptibility testing
via Google News
The Latest on: Antibiotic susceptibility testing
- Antimicrobial Susceptibility Test Market is Estimated to Progress at a CAGR of 4.9% during the Forecast Period, observes TMR Studyon August 1, 2022 at 5:30 am
Increase in government expenditure is likely to propel the global market for antimicrobial susceptibility test during the forecast periodWilmington, Delaware, United States, Aug. 01, 2022 (GLOBE ...
- Global Antimicrobial Susceptibility Testing Market Size Is Expected To Grow At A CAGR Of Approx. 7% From 2022 To 2032on July 29, 2022 at 4:31 am
Evolve Business Intelligence published a new market research report on Global Antimicrobial Susceptibility Testing Market by Product Type (Manual Antimicrobial Susceptibility Testing Products ...
- OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian ...on July 26, 2022 at 7:16 am
Collaborators aim to develop and evaluate computation tools, including predictive models for whole genome sequencing-based antibiotic susceptibility testing (wgsAST) Ares plans to strategically ...
- Ares Genetics, Belgian Infectious Disease Center Partner on Computational Dx Toolson July 26, 2022 at 7:10 am
Ares, a subsidiary of OpGen, will work with the Belgian National Reference Centre for invasive S. pneumoniae to develop the computational tools.
- 6% Of Children Show Covid Symptoms At 90 Days In Hospital Testson July 25, 2022 at 5:47 am
(Bendix, 7/23) In non-covid research — CIDRAP: Rapid Susceptibility Test Shortens Time To Oral Antibiotics, Hospital Stay A randomized clinical trial found that a rapid phenotypic antimicrobial ...
- AMR: One Health Approach Gains Momentum in Kenyaon July 21, 2022 at 5:00 pm
By Mary HeartyAntimicrobial resistance (AMR) is one of the most complex public health threats with root causes in multiple sectors ranging from health, food safety, and agriculture, to environment and ...
- Thanks to COVID-19, alarm grows over drug resistant infectionson July 20, 2022 at 9:43 am
Superbugs’ may have benefited from the pandemic, as use of antibiotics grew and vaccination and sanitation programmes were curtailed.
- CDC, Abbott, Roche, BioMérieux Get FDA 510(k) Clearances in Juneon July 19, 2022 at 8:00 am
The CDC's orthopoxvirus PCR primers and probe set received clearance, along with Roche's assay for the determination of anti-Müllerian hormone.
- Antimicrobial Susceptibility Testing Market Size with Growth Statistics 2022 Key Segmentation and Competitive Strategy till 2030on July 19, 2022 at 7:09 am
The global antimicrobial susceptibility testing market is forecast to grow at a compound annual growth rate (CAGR) of more than 6% during the forecast period from 2021-2030. AST stands for ...
- New machines to reduce turnaround timeon July 18, 2022 at 9:28 pm
VITEK 2 Compact is designed to provide identification and Antibiotics Susceptibility Test results in 5 to 10 hours while conventional methods take 18- 24 hours according to a press release from the ...
via Bing News